Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences

2/5/2013 4:05 PM EST

Raptor Pharmaceutical Corp.
Press release

Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences

NOVATO, Calif., 2013-02-05 22:05 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical
Corp. (Nasdaq:RPTP), today announced that the company's management will present
at two upcoming investor conferences in February. Julie Anne Smith, executive
vice president, strategy and chief operating officer of Raptor, will present an
overview of the company at the 15th Annual BIO CEO & Investor Conference on
February 12, 2013, at 11:00 a.m. ET/8:00 a.m. PT. Christopher M. Starr, Ph.D.,
Raptor's CEO and Julie Anne Smith will present at the Leerink Swann Global
Healthcare Conference on February 12, 2013, at 8:30 a.m. ET/5:30 a.m. PT. Both
conferences will be held at the Waldorf-Astoria in New York. 

A live audio webcast and 14-day archive of the 15th Annual BIO CEO & Investor
Conference presentation will be available at
http://ir.raptorpharma.com/events.cfm. 

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical is an emerging biopharmaceutical company focused on
developing and commercializing life-altering therapeutics that treat
debilitating and often fatal diseases. The company is currently focused on the
development of its first product candidate, RP103 (delayed-release oral
cysteamine bitartrate), as a potential treatment for nephropathic cystinosis, a
rare genetic disorder. In addition to cystinosis, the company is also testing
RP103 for the potential treatment of non-alcoholic steatohepatitis, or NASH, a
metabolic liver disorder, and Huntington's Disease, or HD, a neurodegenerative
disorder. 

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180 


         Georgia Erbez
         Chief Financial Officer
         Raptor Pharmaceutical Corp.
         (415) 382-8111 x204